BioSpace News Archive

Drug Development

Primary Analysis Results From Novartis Pivotal JULIET Trial Show Kymriah (Tisagenlecleucel) Sustained Complete Responses at Six Months in Adults With r/r DLBCL, a Difficult-to-Treat Cancer

The data from this pivotal trial, led by researchers from the University of Penn, show an ORR of 53%, 42% 64%; p<0.0001, with 40% achieving a CR and 14% achieving a PR among 81 infused patients with three or more months of follow-up or earlier discontinuation.

December 10, 2017
·
17 min read
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.

December 10, 2017
·
13 min read
Drug Development

bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia at American Society of Hematology Annual Meeting

bluebird bio announced data from two studies of its LentiGlobin gene therapy product candidate in patients with transfusion-dependent β-thalassemia (TDT).

December 10, 2017
·
10 min read